Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04780841 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
A Phase 2 study of Hyperkalemia, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
- 6
- Study locations
NCT04780841: Completed Phase 2 study of Hyperkalemia, sponsored by Ardelyx.
NCT04780841 is a Phase 2 study of Hyperkalemia that has completed, run by Ardelyx. The registered enrollment target is 109 participants, above the 48-participant average among 8 other Hyperkalemia trials with a reported enrollment target (127% higher). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04780841, a Phase 2 study of Hyperkalemia, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the ability of RDX013 to lower serum potassium in patients with chronic kidney disease with elevated serum potassium levels
Primary Outcome
To evaluate the change of serum potassium from baseline to the end of treatment with different doses of RDX013 to identify the optimal dose for further evaluation in Part B of the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RDX013
Study Locations (6)
Florida
- Horizon Research Group LLC - Coral Gables
- Panax Clinical Research LLC - Miami Lakes
- South Florida Research Phase I-IV; Inc. - Miami Springs
Louisiana
- NW Louisiana Nephrology Assoc - Shreveport
Missouri
- Clinical Research Consultants - Kansas City
North Carolina
- Mountain Kidney & Hypertension Associates - Asheville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2021-01-11 |
| Est. Completion | 2022-03-03 |
| Phase | Phase 2 |
What the finished NCT04780841 record still lists
NCT04780841 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, above the 48-participant average among 8 other Hyperkalemia trials with a reported enrollment target (127% higher).
The record links to 1 condition, with Hyperkalemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04780841 lists 6 locations in 4 states (Florida, Louisiana, Missouri).
Frequently Asked Questions
What is clinical trial NCT04780841 about?
NCT04780841 is a clinical study titled "A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia". The purpose of this study is to evaluate the ability of RDX013 to lower serum potassium in patients with chronic kidney disease with elevated serum potassium levels
What is the current status of trial NCT04780841?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2021-01-11. Estimated completion is 2022-03-03.
What conditions does trial NCT04780841 study?
This clinical trial studies the following conditions: Hyperkalemia.
What interventions are being tested in trial NCT04780841?
The interventions under investigation include: Placebo (DRUG), RDX013 (DRUG).
Who is sponsoring clinical trial NCT04780841?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04780841 being conducted?
This trial has 6 study locations across Florida, Louisiana, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperkalemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04780841's enrollment target sits among peer trials
109 2nd of 8 the highest of 8 other Hyperkalemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hyperkalemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
RECRUITING · Phase 2
-
Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia
COMPLETED · Phase 2
-
Evaluation of Patiromer in Heart Failure Patients
COMPLETED · Phase 2
-
AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring
RECRUITING
-
Adding Urea to the Final Dialysis Fluid
RECRUITING · Phase 1
-
Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI